What Can You Expect in 2026
With global cases of AMD, DME, and glaucoma rapidly increasing, ophthalmic drug R&D is accelerating to meet urgent unmet needs. However, poor treatment adherence, invasive procedures, and adverse side effects continue to limit therapeutic success, highlighting the critical need for optimized delivery approaches.
Recent developments, including Genentech’s Susvimo label expansion, advances in sustained-release and suprachoroidal delivery systems, and Regeneron’s acquisition of Oxular, demonstrate a growing industry focus on improving durability and reducing invasiveness.
That’s why 80+ industry leaders will gather at the 4th Ophthalmic Drug Delivery Summit this January to explore long-acting intravitreal and subretinal innovations, emerging suprachoroidal techniques, novel formulation strategies, drug-device integration, and evolving regulatory expectations.
Join experts across preclinical and clinical R&D, formulation, pharmacology, devices, and combination products for three days of focused discussions driving the future of safe, effective, and durable ophthalmic therapies.
Gain Hands-On Insights from Re-Vana on Long-Acting Biologic Formulation
Join Professor Thakur Singh to explore formulation and pre-clinical strategies for overcoming biologic instability and translating long-acting delivery systems into clinical success
Explore Academic Advances in Pharmacokinetics & Natural Nanocarriers
Hear from Arto Utti and Kirsi Rilla on intravitreal PK modeling and extracellular vesicles as emerging tools for safer, targeted, and sustained ocular drug delivery
Connect with Leaders Driving the Future of Ophthalmic Innovation
Engage in Speed Networking to connect with top pharma, biotech, and academic minds advancing ophthalmic delivery and fostering real-world innovation
Unlock Real-World Innovation Through Biotech-Pharma Collaboration
Learn how Ripple Therapeutics and AbbVie are accelerating delivery innovation through early alignment, strategic collaboration, and shared execution strategies
Discover How Suprachoroidal Delivery is Redefining Retinal Access
Explore how Clearside Biomedical and Everads Therapy are using next-gen injection devices to achieve safer, simpler, and more targeted delivery to the posterior segment
Explore the Full Event Guide
- 3 Days Dedicated to Ocular Drug Delivery InnovationÂ
- 22+ Expert Speakers Across Pharma, Biotech, & Academia
- Exclusive Networking with Leading Ocular R&D Decision-MakersÂ
- Insights from Delivery Scientists & Formulation Specialists to Regulatory Experts
- Real-World Case Studies from Industry Giants & Emerging InnovatorsÂ
Attending Companies Include
Explore the Agenda
Discover the latest innovations transforming ocular drug delivery, from long-acting implants to suprachoroidal access.Â
Partner With Us
Connect with top-tier drug developers actively seeking expert collaborators across formulation, devices, imaging, and more.Â
Join Other Ocular Delivery Experts
Register now and look forward to networking with 80+ leading scientists and innovators advancing the future of ophthalmic therapeutics.Â